Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
CytoMed Therapeutics Limited Ordinary Shares(GDTC)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for GDTC
09/24/2026: GDTC (1-star) is currently NOT-A-BUY. Pass it for now.
CytoMed Therapeutics is a pre-clinical stage biotechnology firm developing allogeneic 'off-the-shelf' cell therapies, specifically focusing on Gamma Delta T cells and NKT cells to treat various cancers. The company's primary strength lies in its proprietary cell-engineering platform, which aims to offer a more scalable and accessible alternative to traditional personalized treatments. Its growth story centers on successfully transitioning these candidates from laboratory research into human clinical trials. Key risks include the high probability of failure inherent in early-stage R&D, heavy reliance on external financing, and intense competition from larger, better-funded biopharmaceutical entities. This stock is suitable only for high-risk, long-term investors monitoring clinical milestones and regulatory progress.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-risk, high-reward exposure to the immunotherapy sector but lacks the proven growth metrics typically sought by growth investors. |
| Momentum investor | Mixed fit | Momentum may occur around clinical data releases, but the stock generally lacks the consistent volume and trend characteristics for traditional momentum strategies. |
| Value investor | Weak fit | As a pre-revenue biotechnology firm, traditional value metrics like P/E ratios are not applicable. |
| Dividend investor | Weak fit | The company is in an early development phase and does not pay dividends. |
| Low-risk investor | Weak fit | The high volatility and binary clinical outcome risks make this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Small-cap biotech stocks frequently experience significant price swings based on news flow and market sentiment. |
| Valuation risk | Medium / high | Determining the fair value of a pre-clinical company is highly speculative and subject to rapid reassessment. |
| Competition risk (immunotherapy competition) | High | Many better-funded competitors are developing similar cell-based therapies, threatening to make CytoMed's candidates obsolete. |
| Business quality | Medium | The company relies on complex R&D execution, which carries high operational risk. |
| Dividend income | Low / none | The company prioritizes R&D spending over shareholder distributions. |
| Execution risk | High | The ability to move from pre-clinical results to successful clinical trials is the primary determinant of long-term value. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -51.76% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/24/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.77M USD | Price to earnings Ratio - | 1Y Target Price 4.16 |
Price to earnings Ratio - | 1Y Target Price 4.16 | ||
Volume (30-day avg) 17.5K shares | Beta 0.05 | 52 Weeks Range 0.68 - 3.68 | Updated Date 09/23/2026 |
52 Weeks Range 0.68 - 3.68 | Updated Date 09/23/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.27 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Cell Therapy R&D | Research and development of CAR-NKT and gamma-delta T cell therapies. | The company is a research project; it does not currently sell any products or generate revenue. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9.50M | Price to Sales(TTM) 12.51 |
Enterprise Value 9.50M | Price to Sales(TTM) 12.51 | ||
Enterprise Value to Revenue 37.39 | Enterprise Value to EBITDA -4.45 | Shares Outstanding 11.83M | Shares Floating 3.49M |
Shares Outstanding 11.83M | Shares Floating 3.49M | ||
Percent Insiders 70.47 | Percent Institutions 0.14 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About CytoMed Therapeutics Limited Ordinary Shares
Exchange NASDAQ | Headquarters - | ||
IPO Launch date 2023-04-14 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 42 | Website https://w2.cytomed.sg |
Full time employees 42 | Website https://w2.cytomed.sg | ||
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore; and Business and Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.